<DOC>
	<DOCNO>NCT00719186</DOCNO>
	<brief_summary>The primary research hypothesis ovulation induction aromatase inhibitor ( letrozole ) likely result live birth ovulation induction selective estrogen receptor modulator ( clomiphene citrate ) infertile woman PCOS . A safety hypothesis also incorporate primary research hypothesis hypothesize treatment equally safe mother child . Secondary research hypothesis include : 1 . Treatment letrozole likely result singleton pregnancy compare treatment clomiphene citrate . Singleton pregnancy define presence single intrauterine gestational sac single fetal pole observable heart motion . 2 . Treatment letrozole less likely result first trim intrauterine fetal demise treatment clomiphene citrate . A first trimester IUFD define pregnancy end 13 week gestation . 3 . Treatment letrozole likely result ovulation ( increase ovulation rate ) compare treatment clomiphene citrate . Ovulation define midluteal progesterone level ≥ 3 ng/mL . 4 . The short time pregnancy letrozole . 5 . Age , body mass index , SHBG , testosterone , LH , Anti-Mullerian Hormone ( AMH ) , degree hirsutism acne significant predictor ovulation conception regardless treatment . 6 . Improvement SHBG , testosterone , AMH , LH level significant predictor ovulation conception regardless treatment . 7 . DNA polymorphisms estrogen action gene predict response study drug . 8 . Quality Life good letrozole clomiphene . 9 . Letrozole cost effective achieve singleton pregnancy clomiphene .</brief_summary>
	<brief_title>Pregnancy Polycystic Ovary Syndrome II</brief_title>
	<detailed_description>Preliminary data promising use letrozole induce ovulation infertile woman PCOS . However true magnitude effect letrozole difficult discern prior study . Therefore intend determine safety efficacy letrozole , aromatase inhibitor , compare clomiphene citrate , selective estrogen receptor modulator , achieve live birth infertile woman PCOS . Treatment- After progestin withdrawal , 750 woman equally randomize two different treatment arm : A ) clomiphene citrate 50 mg every day 5 day ( day 3-7 cycle ) , B ) letrozole 2.5 mg every day 5 day ( day 3-7 cycle ) , total 5 cycle 20 week . Dose increase subsequent cycle treatment group non-response poor ovulatory response maximum 150 mg clomiphene day ( x 5 day ) 7.5 mg letrozole day ( x 5 day ) . Statistical Analysis- The primary analysis use intent-to-treat approach examine difference live birth rate two treatment arm . Anticipated time completion- A total 4 year require complete study start ; 31 month enrollment period , 5 month treatment period , 9 month additional observation determine pregnancy outcomes . This accomplish enrol ~3.45 woman PCOS per center per month enrollment period ( N = 7 RMN site ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Key Inclusion Criteria ( Must ovulatory dysfunction either hyperandrogenism PCO ) 1 . Chronic anovulation oligomenorrhea : define spontaneous intermenstrual period ≥45 day total ≤8 menses per year , woman suspect anovulatory bleeding , midluteal serum progesterone level &lt; 3 ng/mL indicative chronic anovulation . For woman ovarian suppressive therapy confound medication ( i.e . insulin sensitize agent ) within last year prior study , history ≤8 menses per year prior initiation prior therapy qualify evidence oligomenorrhea . For woman regular bleeding pattern , suspect experience anovulatory bleeding , midluteal progesterone level &lt; 3ng/mL evidence ovulatory dysfunction qualify anovulation . Undiagnosed persistent vaginal bleeding diagnose treated prior enrollment . 2 . Hyperandrogenism ( either Hirsutism Hyperandrogenemia ) Polycystic Ovaries Ultrasound : 1 . Hirsutism determine modify FerrimanGallwey Score &gt; 8 screen exam ( Hatch , Rosenfield et al . 1981 Aug 1 ) . Subjects hirsutism need local core lab document elevate androgen level . 2 . Hyperandrogenemia determine local lab . Local cutoff predetermine site prior study initiation . Hyperandrogenemia define elevated total testosterone , free androgen index ( FAI ) ( lab Penn State College Medicine total T &gt; 50 ng/dL free androgen index &gt; 5 ) allow entry study ( Legro , Driscoll et al . 1998 ) . The FAI calculate measurable value total T SHBG , previously describe ( Miller , Rosner et al . 2004 ) , use follow equation : ( FAI = Total testosterone nmol/L / SHBG nmol/L ) X 100 . Outside lab value obtain within last year document elevate T FAI level sufficient meet criterion hyperandrogenemia . 3 . Polycystic Ovaries Ultrasound : We use revise Rotterdam criterion diagnose polycystic ovary ( Balen , Laven et al . 2003 ) . PCO define either ovary contains 12 follicle measure 29 mm diameter , increase ovarian volume ( &gt; 10 cm3 ) one ovary entry study . If follicle &gt; 10 mm diameter , scan repeat time ovarian quiescence order calculate volume area subject otherwise qualify study . The presence single polycystic ovary ( PCO ) , either volume morphology , sufficient provide diagnosis . We exclude subject medical condition represent contraindication CC , aromatase inhibitor and/or pregnancy unable comply study procedure . We exclude subject poorly control Type I Type II diabetes ; undiagnosed liver disease dysfunction ( base serum liver enzyme test ) ; renal disease abnormal serum renal function ; significant anemia ; history deep venous thrombosis , pulmonary embolus , cerebrovascular accident ; uncontrolled hypertension , know symptomatic heart disease ; history suspect cervical carcinoma , endometrial carcinoma , breast carcinoma ; undiagnosed vaginal bleeding , use medication know affect reproductive function metabolism ( e.g. , OCP , GnRH agonists antagonist , antiandrogens , gonadotropin , antiobesity drug , somatostatin , diazoxide , ACE inhibitor , calcium channel blocker ) . As PPCOS allow 2 month washout period subject desire participate discontinue exclusionary medication ( commonly OCP , also possibly metformin ) , period observation treatment correctable condition . Couple Inclusion Criteria 1 . Sperm concentration 14 million/mL least one ejaculate within last year , least motile sperm . 2 . Ability regular intercourse ovulation induction phase study . 3 . At least one patent tube normal uterine cavity determine sonohysterogram , hysterosalpingogram , hysteroscopy/laparoscopy within last 3 year . An uncomplicated intrauterine nonIVF pregnancy uncomplicated delivery postpartum course result live birth within last three year also serve sufficient evidence patent tube normal uterine cavity long subject , pregnancy subsequently , risk factor Asherman 's syndrome tubal disease disorder lead increase suspicion intrauterine abnormality tubal occlusion . 4 . No previous sterilization procedure ( vasectomy , tubal ligation ) reverse . The prior procedure may affect study outcome . Specific Exclusion Criteria 1 . Current pregnancy . 2 . Patients oral contraceptive , depoprogestins , hormonal implant ( include Implanon ) . A two month washout period require prior screening patient agent . Longer washouts may necessary certain depot contraceptive form implant , especially implant still place . A onemonth washout require patient oral cyclic progestin . 3 . Patients hyperprolactinemia ( define two prolactin level least one week apart &gt; 30 ng/mL determine local normative value ) . The goal eliminate patient document hyperprolactinemia decrease heterogeneity PCOS population . These patient may candidate ovulation induction alternate regimen ( dopamine agonist ) . A normal level within last year treatment adequate entry . 4 . Patients know 21hydroxylase deficiency enzyme deficiency lead phenotype congenital adrenal hyperplasia . 21hydroxylase deficiency exclude patient fast 17hydroxyprogesterone ( 17OHP ) level &lt; 2 ng/mL ( Azziz , Hincapie et al . 1999 Nov ) . If relevant , level determine follicular phase , 17hydroxyprogesterone level likely elevate beyond range patient luteal phase infrequent ovulatory cycle . In case elevate fast 17OHP level follicular phase , ACTH stimulation test perform . A 1hour stimulate value &gt; 10 ng/mL exclusion ( Moran , Knochenhauer et al . 1998 ) . As 21hydroxylase deficiency congenital condition , normal level past 17hydroxyprogesterone allows entry study . 5 . Patients menopausal level FSH ( &gt; 15 mIU/mL ) . A normal level within last year adequate entry . 6 . Patients uncorrected thyroid disease ( define TSH &lt; 0.2 mIU/mL &gt; 5.5 mIU/mL ) . A normal level within last year adequate entry . 7 . Patients diagnose Type I Type II diabetes poorly control ( define glycohemoglobin level &gt; 7.0 % ) , patient receive antidiabetic medication insulin , thiazolidinediones , acarbose , sulfonylurea likely confound effect study medication ; patient currently receive metformin XR diagnosis Type I Type II diabetes PCOS also specifically exclude . 8 . Patients liver disease define AST ALT &gt; 2 time normal total bilirubin &gt; 2.5 mg/dL . 9 . Patients renal disease define BUN &gt; 30 mg/dL serum creatinine &gt; 1.4 mg/dL . 10 . Patients significant anemia ( Hemoglobin &lt; 10 g/dL ) . 11 . Patients history deep venous thrombosis , pulmonary embolus , cerebrovascular accident . 12 . Patients know heart disease likely exacerbated pregnancy . 13 . Patients history , suspect cervical carcinoma , endometrial carcinoma , breast carcinoma . A normal Pap smear result within ACOG guideline Pap smear frequency require woman 21 . 14 . Patients current history alcohol abuse . Alcohol abuse define &gt; 14 drinks/week binge drinking . 15 . Patients enrol simultaneously investigative study require medication , proscribe study medication , limit intercourse , otherwise prevent compliance protocol . Patients anticipate take longer one month break protocol enrol . 16 . Patients take medication know affect reproductive function metabolism . These medication include oral contraceptive , GnRH agonists antagonist , antiandrogens , gonadotropin , antiobesity drug , antidiabetic drug metformin thiazolidinediones , somatostatin , diazoxide , ACE inhibitor , calcium channel blocker . The washout period medication two month list find appendix . 17 . Patients suspect adrenal ovarian tumor secrete androgen . 18 . Patients suspect Cushing 's syndrome . 19 . Couples previous sterilization procedure ( vasectomy , tubal ligation ) reverse . The prior procedure may affect study outcome , patient reverse sterilization procedure PCOS rare enough exclusion adversely affect recruitment . 20 . Subjects undergone bariatric surgery procedure recent past ( &lt; 12 month ) period acute weight loss advise pregnancy bariatric surgeon . 21 . Patients untreated poorly control hypertension define systolic blood pressure ≥ 160 mm Hg diastolic ≥ 100 mm Hg obtain two measure obtain least 60 minute apart .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Polycystic Ovary Syndrome</keyword>
	<keyword>Infertility</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Women</keyword>
</DOC>